Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification.
Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.
[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal.]
Graves' disease after treatment with Alemtuzumab for multiple sclerosis.
Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Can smoking aggravate my multiple sclerosis symptoms?
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Human neural precursor cells promote neurologic recovery in a viral model of multiple sclerosis.
Natalizumab in relapsing-remitting multiple sclerosis.
Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Disclosing the diagnosis of multiple sclerosis: The Profile Project.
[Side-effects of glucocorticosteroids in multiple sclerosis: a case report of a patient with global amnesia.]
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
Center for Drug Evaluation and Research Approval Letter, application number: 21-897
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells.
Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination.
Simvastatin: a review.
Preventive healthcare use among males with multiple sclerosis.
Simvastatin: two decades in a circle.
Modeling the heterogeneity of multiple sclerosis in animals.
Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.

Pages